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PR~)IC't~RS OF INSTITUTICRRLIZATIC~ AMONG PATII~TS WI%~i 
AI~D~R'S DIm~%SE RRD ~ I ~ ' Z ' I I ~ S .  *Mona B a ~ r t e n ,  
Ruhln Becket (St. Justine Cummuaity Health Department and 
McGill University, Montreal, Canada). 
The social, psychological, and economic co~ts associated 
with Lnstitutiomalization of the depemdemt elderly are high. 
Therefore, a major mmmag~me~t goal in the care of patients with 
Alshaimer's disease or another dememtia is to maintain the pa- 
tient in the community for as long as possible. As part of a 
stuc~ on the health of fmuily caregivers (CGs) of patients with 
dementia, our o~jective was to identify characteristics of 
patiemts and CGe which were predictive of institutionalization 
over a one year interval. Patients (n=85) with a D~4-III 
dla~mosis of d~memtia were recruited from the geriatric 
assemmemt unit of a large Montreal teachin9 hospital. All 
patients were residing in the commm~ity when the study began. 
Those who were referred to the geriatric trait specifically for 
pre-placsmemt asseesment or for a serious, acute medical prob- 
lem were excluded. Data were obtained through h(ne interviews 
with the family CG and from the geriatric unit's medical 
charts. At ~me-year follow-up, 8% of the patients had died and 
34% had beem instituticrmlized; patients who had died were not 
included in  stthsequent analyses. Whea% contrasted with patients 
who were still livin~ in the ccmmm/ty, patients who had been 
irmtituti(~alized were si~/ficamtly older and more co~nitively 
in, aired, and had a hi~her level of d ~ c e  with respect to 
activities of daily living. They were also more likely to be 
male and had a longer mean duration of dementia, although these 
varia~las were not statistically significant. Patients whose CG 
was a child rather than the spouse had a kigher probability of 
imstituticnalizatien. A higher baseline level of depressien 
amm~ OSm was predictive of instltutionalizaticn, although the 
OG's physical health status (as measured by the number of re- 
ported chronic cca~iltiens) was not. A I ~  most of the 
factors predictive of instituticmalisation are not preventable, 
knowledge of these factors can help clinicians and ccmmm~ity 
health practitioners to target patients and f~,ilies who are at 
high risk, and to implement appropriate preventive and 
therapeutic strategies. 
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FAMILIAL ALZHEIMER'S DISEASE: STUDY OF A NEW ITALIAN 
KINDRED. L. Bergamini, * I. Rainero, L. Pinessi, G. 
Vaula; Dept. of Neurology, Univ. of Turin (Italy); 
A.C. Bruni, G. Gel, M.P. Montesi, C, Ermio; Dept. of 
Neurology, Lamezia Terms (Italy); and J.F. Foncin; 
Hop. La Salp~tri~re, Paris (France). 
We have recently discovered in Torino (Italy) a 
new pedigree with Familial Alzheimer's disease. The 
index patient is a woman who became demented at age 
43. Several relatives have had a history of dementia. 
The ancestors of th e patient were from Calabria 
(Southern Italy) and members of the family emigrated 
to the North of Italy, to France and to the USA. 
At present, the "Torino family" comprises 1085 
members, distributed in 8 generations.24 members 
affected with Alzheimer's disease have been 
identified: 5 were diagnosed by personal examination, 
12 by medical records and 7 by history. Mean age at 
death of the patients is 50.5 ± 9.2 yr (range 43-59). 
The pedigree is consistent with autosomal dominant 
inheritance. 
The "Torino family" shows several similaritSes with 
the Family N, described by Foncin et al. (i): the 
ancestors were born in the same country of Calabria, 
neurological and psychiatric symptoms are the same in 
the two families and no difference in age at onset of 
the disease and age at death was found. 
to find a direct linkage between these two 
Molecular genetic of this new family is 
under investigation. 
1. Foncin JF et al. Rev. Neurol (Paris) , 
202,1985. 
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DIFFERENCES IN POSTURAL SWAY PATTERNS IN INDIVIDUALS WITH 
ALZHEIMER DISEASE WITH AND WITHOUT HISTORY OF FALLS: A Pilot 
Study. A Bhattaeharya and C. Cox, Dept. of Environmental 
Health; S. Gllster, Alois Alzheimer Center; A. McCracken, 
College of Nursing; and G. Warshaw. Geriatric Division of the 
University of Cincinnati Medical School; Cincinnati, Ohio, 
U.S.A.  
P e r s o n s  w i t h  A l z h e l m e r ' s  D i sea se  (AD) have  more t h a n  t h r e e  
times the risk of falling than cognitlvely healthy elderly 
persons. Regardless of the physiological conditions for which 
falling is a marker, the most significant risk factor is the 
impairment of postural balance. In an effort to determine the 
ability to perform quantitative postural sway measurements in 
the subjects with AD and differences in postural sway patterns 
in patients with and without history of falls, a pilot study 
with 2 male and 2 female patients was performed. Out of 4 pa- 
tients (mean age: 84.7 yrs.), 2 had previous history of falls. 
Postural sway testing was conducted on these patients with Hay- 
cox Rating Scale scores of 16 to 26. The postural balance or 
sway was noninvasively quantitated with a microprocessor-based 
force platform system. Each patient performed four tasks i.e., 
EO: Eyes open on force plate; EC: Eyes closed on force plate; 
FO; Eyes open on foam pad placed on the force plate; and FC: 
Eyes closed on foam pad placed on the force plate. This test 
allows quantification of the movement pattern of body's center 
of pressure associated with postural sway. These tests were 
designed to indirectly evaluate the roles of vision, proprio- 
ception and the vestibular system for postural balance. The 
patients with previous history of falls had difficulty in com- 
pleting FO and FC tests. In particular, postural sway responses 
for the fallers were significantly larger than the nonfallers 
for the FO(up to 3.9 times) and FC(up to 4.7 times) tests where 
the vestibular system is placed at a higher challenge compared 
to EO and EC tests. Furthermore, frequency of sway patterns in 
the fellers (0.08 Hz for lateral sway and 0.ii Hz for anterior- 
posterior[A-P] sway) were low compared to the nonfallers(0.18 Hz 
for lateral sway and 0.23 Hz for A-P sway) which is consistent 
with vestibular-controlled postural balance characteristics. In 
summary, the result of our above-mentioned case study indicates 
that postural sway testing can be safely performed in the 
Alzheimer patients and there exists a significant difference in 
postural sway response between fellers and nonfallers. 
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APPLICATION OF RESEARCH CRITERIA FOR DEMENTIA IN COMMON CUNtCAL 
PRACTICE *F.R.J. Vethey, R.W.H.M. Ponds, E.J. Reyetson van BtJumm, F.W. 
Vree.ng a.d J. JoU~, I~mrtments of Neuropsychotogy and ~ =rid 
*Noufology; U ~  of Limbutg, P.O. Box 616. 6200 MD blaa~Mht, The 
Nethedand,* 
Recently, diagnostic criteria were proposed for the clinical and 
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that the extensive approach as recommended for research leads to substantial 
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ABSTRACTS OF SECOND INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE 
BRAIN AMYLOIDOSIS 
299 
changes in diagnostic outcome, compared to procedures in daily practice. Most of 
the discrepancies pertain to the evaluation of the clinical condition. This undedines 
the importance of a thorough, albeit time consuming, clinical evaluation, which 
cannot he replaced by laboratory end X-ray data. The diagnosis of dementia and 
dementing diseases should be based on an integrated multi-disciplinary and 
systematic model, with explicit definitions of terms and taking into account all in- and 
exclusion criteria. 
B R A I N  A M Y L O I D O S I S  
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PATHOGENESIS OF BETA-AMYLOID FIBER FORMATION, 
*H.M. Wisniewski, J. Wegiel, A.W. Vorbrodt, M. Wrzolek, J.R. Currie, 
NYS institute for Basic Research in Developmental Disabilities, 
Staten Island, NY 10314 (USA) 
Amyloid deposition in the brain accompanies normal aging and AD 
as well as unconventional viral disease and Down's syndrome. In each 
case, the amyloid deposits exhibit generally similar morphologies but 
with differences characteristic for each condition. In all of the above 
mentioned conditions, the presence of amyloid fiber deposits appears 
to be limited to the CNS. However, by means of in situ hybridization and 
immunohistochemical methods, it has been shown that many cell types 
within and outside the CNS could be the source of the beta-protein in 
AIzheimer disease (AD). Uitrastructural studies strongly indicate that the 
resident macrophage population of cells in the brain, the microgtia, are 
the cells producing the beta-amyloid fibers. These cells, which contain 
a labyrinth of amyloid-filled channels, show a clear polarity in relation to 
the amyloid deposits. The amyloid fibers appear to form in altered 
cisterns of endoplasmic reticulum, and there is some indication that the 
beta-protein may bypass the Golgi complex. Because the amyloid fibers 
are first seen in the distended cisterns of the smooth endoplasmic 
reticulum system, it appears that these cells are engaged in the 
formation, not the phagocytosis, of the amyloid fibers. The configuration 
of extracellular bundles of amyloid fibrils radiating from indentations in 
the cytoplasm of Kupffer and reticular cells of the liver and spleen in 
systemic amyloidosis has been found to be identical in many details 
with amyloid star formation by microglial cells in AD brain. We 
hypothesize that the microglia/macrophagas (which are probably both 
the producer and processor cells) synthesize and secrete the beta- 
peptide either as an overexprassed, truncated gene product or as an 
aberrant peptide resulting from abnormal post-translational processing. 
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AMYLOID BA4 PROTEIN PATHOLOGY IS CENTRAL TO THE CAUSE OF 
~ ' S  DISEASE 
"IC Beyreether, W. Schubert, G. Multhaup, J.M. Salbaum, J. Beer, C. Hilbich, G. 
KOnig, T. Dyrks, A. Weidemann, P. Fischer, D. Bunke, U. MOnning, N. Catternccia, 
H. Mechler, R. Prior, T. Kitamoto, E. Schlichtmann, E. Mack-K0hn, C.L. Masters # 
ZMBH, Center for Molecular Biology, University of Heidelberg, F.R.G. 
#Department of Pathology, University of Melbourne, ParkviUe, Victoria 3052 
Australia 
On the molecular level Alzheirner's disease (AD) is characterized by amyloid 
BA4 protein, which accumulates pdmarily in the hippocampus and neocortex. 
The massive deposition of fibrillar BA4 protein aggregates found in AD brain is 
rendrWscent of storage diseases. The precUnical period of amyioio BA4 protein 
accumulation was estimated by us to approximate 30 years. 
Since the same molecular neuropathological changes are observed in 
trisomy 21 Down~J syndrome, the AD amylold 8A4 pathology is suggested to 
be due to abnormal expression of genes located on human chromosome 21. 
The demonstration of the gene (PAD/APP) encoding the amylold precursor 
protein (Pre hA) to map to chromosome 21 strongly supports our hypothesis 
that this germ and its pathological product is central to the causation of AD. 
The e~on structure of the PAD gene revealed that amylold BA4 protein can 
not be produced by alternative splicing and therefore has to be generated by 
abnormal pathological degradation of tranarnembrane Pre A4 proteins which in 
contrast to secretory Pre A4 proteins include the BA4 sequence as part of the 
ecto- and transmembrane domains. 
Since the amyloidogenic transmembrane Pre A4 proteins are abundantly 
expressed in neurons, antedogradely transported in axons and located at 
synapses, the pathological degradation to BA4 protein has to occur either in 
neurons or between synapses. 
Thus, chronic extra- and intracellular amyioid BA4 protein formation in brain 
would occur at sites relevant for impairment of intellectual functions, gradually 
reduce the synaptic density and finally result in the clinical features of AD. 
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AMYLOID B-PROTEIN DEPOSITION AS A SEMINAL PATHOGENETIC 
EVENT IN AD: AN HYPOTHESIS. *D,J. Selkoe. Harvard Medical 
School and Brigham and Women's Hospital, Boston, MA 02115. 
Evidence emerging from numerous laboratories during the last 
two years suggests that amorphous, largely non-fibrillar deposits 
of the amyloid B-protein (ABP) precede the development of neuri- 
tic plaques, neurofibrillary tangles, gliosis and other cytologi- 
cal changes in Alzheimer's disease (AD) and Down's syndrome (DS). 
We studied such diffuse plaques to advantage in AD cerebellum and 
striatum, where they are virtually the only form of ABP deposit 
found even at the end of the disease (Joachim et al., Am. J. Path. 
135:309, 1989 and J. Neuropath. Ex~. Neurol. 87:330, 1989). If 
local neuronal/neurltic alteration were a prerequisite for ABP 
deposition, one would expect some morphological evidence of 
neuritic abnormality after years of cerebellar and striatal ABP 
deposition, particularly since profound neuritic pathology sur- 
rounds many ABP deposits in cerebral cortex. Similarly, sizable 
numbers of diffuse ABP deposits can be found in some 25-35 year 
old DS subjects at a time when no neuritic or glial abnormality 
is detectable. Recently, we discovered ABP-immunoreactive 
deposits in vessels and/or perivascular tissue of skin and other 
non-neural tissues in AD and DS, suggesting that ABP deposition 
can occur in the absence of neuronal or glial injury, indeed, in 
the absence of neurons and glia. These and other observations all 
strongly suggest that B-amyloidosis in AD, like other better 
characterized amylodioses, is not secondary to local cellular 
change but precedes it. We, therefore, hypothesize that in normal 
aging, an alternate, minor pathway for APP proteolytic processing 
exists that results in release of amyloidogenic fragments of APP 
containing the intact ABP region. In DS, this alternate pathway, 
which is normally used at a low level, is overutilized due to the 
increased expression of APP molecules that results from higher 
gene dosage. In FAD, rearrangements or mutations on ch. 21 (in 
at least some families) lead to a dysregulation of APP biosynthe- 
sis that results in more APP molecules being processed through 
the minor pathway and increased genesis of ABP, producing a 
histologic phenotype that is indistinguishable from that of DS. 
The progressive deposition of ABP in DS and FAD initiates. 
either directly or indirectly, a cascade of secondary cellular 
changes (including local neurite growth) that, over years or 
decades, produce neuronal dysfunction and thus dementia. 
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ROLE OF IMMUNE FACTORS IN AMYLOIOOGENESIS IN ALZHEIMER BRAIN 
T. Ish i i ,  S. Haga, M. Satoh, and F. Kametani, Psychiatric 
Research Institute of Tokyo, Setagaya-Ku, Tokyo 156, Japan. 
The earl iest stage of deposition of amyloid protein and f i b r i l  
formation (amyloidogenesis) in the Alzheimer brain was studied 
by immunohistochemical methods using antibodies to subsequences 
of amyloid precursor protein (APP), immunoglobulins (IG), 
complements (CP),~l-antichymotrypsin (ACT) and microglia. 
IG, CP Clq, C4, C3 and ACT are present in "diffuse plaques" 
which are thought to be the earl iest stage of amyloid deposition. 
In addition, the monoclonal antibody to senile plaques which was 
reported previously (Ishi i  et a l . ,  Neuropathol & Appl Neurobiol 
12, 1986) proved to react with epitopes in the l ight chain of 
IGs, thus indicating the presence of the la t ter  epitopes in 
close association with the amyloid f i b r i l s  in the Alzheimer 
brain. In the case of complement immunohistochemistry, immuno-EM 
pictures revealed the deposition of a homogeneous material 
(probably preamyloid substance) near the immunoreactive amyloid 
f i b r i l s ,  indicating the possible role of CP f ixat ion in f i b r i l  
formation. Microglial cells are few in number in the area of 
diffuse plaques but later the numbers increase and microglia 
accumulate in and around mature plaques. The above immunological 
factors are thought to be secreted by activation of macrophages 
through interleukin l and the process may be interpreted as a 
kind of chronic inflammation. The problem is what kind of antigen 
or antigens stimulate such an immunological response in the 
process of amyloid deposition in the Alzheimer brain. 
Aberrant catabolism of APP with membrane damage is proposed 
as the cause of amyloid formation. Certainly trophic as well as 
toxic effects of#-protein are reported. However, abnormal 
breakdown products of physiological substances usually lead to 
